Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

134
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
134
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

125
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
125
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

99
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
99
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

85
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
85
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

71
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
71
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

119
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
119

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world prevalence and prognostic significance of hepatotoxicity after chimeric antigen receptor T-cell therapy.

British journal of haematology·2026
Same author

Association of prior beta-blocker treatment and outcome in patients with out-of-hospital cardiac arrest.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Acute Upper Gastrointestinal Bleeding is Associated With Poor Prognosis in Patients With Biliary Tract Cancer.

Cancer medicine·2026
Same author

[Updated management algorithm: non-invasive ventilation (NIV)].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2026
Same author

[Action algorithm: management of long lie trauma in clinical acute and emergency medicine].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2026
Same author

Recent Advances in the Diagnosis and Management of Clinically Significant Portal Hypertension in Liver Cirrhosis: A Clinical Review.

Biomedicines·2026

Related Experiment Video

Updated: Oct 23, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K

[Cirrhotic cardiomyopathy].

Philipp Kasper, Hans-Michael Steffen, Guido Michels

    Deutsche Medizinische Wochenschrift (1946)
    |August 20, 2021
    PubMed
    Summary
    This summary is machine-generated.

    Cirrhotic cardiomyopathy (CCM) involves heart dysfunction in advanced liver disease, often hidden until stress. Early cardiac evaluation is key for managing risks in these patients.

    More Related Videos

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
    05:14

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

    Published on: May 16, 2020

    5.0K
    Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
    10:08

    Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

    Published on: February 17, 2018

    13.7K

    Related Experiment Videos

    Last Updated: Oct 23, 2025

    Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
    03:45

    Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

    Published on: August 8, 2022

    3.8K
    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
    05:14

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

    Published on: May 16, 2020

    5.0K
    Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
    10:08

    Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

    Published on: February 17, 2018

    13.7K

    Area of Science:

    • Cardiology
    • Hepatology
    • Internal Medicine

    Background:

    • Cirrhotic cardiomyopathy (CCM) is a cardiac dysfunction in end-stage liver disease.
    • It presents as systolic and/or diastolic dysfunction without prior heart conditions.
    • Cardiac issues are often unapparent at rest but emerge during physiological stress.

    Purpose of the Study:

    • To review the characteristics and diagnostic challenges of cirrhotic cardiomyopathy.
    • To highlight the importance of cardiac evaluation in patients with liver disease.

    Main Methods:

    • Diagnosis relies on echocardiography to detect subclinical cardiac dysfunction.
    • Additional criteria include electrophysiological abnormalities (e.g., QT prolongation).
    • Biomarkers (natriuretic peptides) and structural changes (left atrium enlargement) are also considered.

    Main Results:

    • CCM is characterized by impaired cardiac function, particularly under stress.
    • Diagnosis requires a combination of imaging, electrophysiological, and biomarker assessments.
    • No specific treatment exists for CCM.

    Conclusions:

    • Management focuses on supportive care and regular cardiac monitoring for high-risk individuals.
    • Cardiac evaluation is crucial for transplant candidates and patients undergoing invasive procedures.
    • Proactive management can mitigate risks associated with CCM in liver disease patients.